Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. - Wikidata - wikimedia - TriplyDB

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

http://www.wikidata.org/entity/Q34757261

about

Oncolytic Viruses: Therapeutics With an Identity Crisis Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?The evolution of poxvirus vaccines Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy Oncolytic viruses as anticancer vaccines Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives Inhibitors of C5 complement enhance vaccinia virus oncolysis.Chemokines as Cancer Vaccine Adjuvants.Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.GLI2 transcription factor mediates cytokine cross-talk in the tumor microenvironment.Immune cells: more than simple carriers for systemic delivery of oncolytic viruses.Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity.Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy.A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro.Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.Progress of oncolytic viruses in sarcomas.Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.Evolution of oncolytic viruses: novel strategies for cancer treatment.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Immunotherapeutic potential of oncolytic vaccinia virus.Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy.Arming oncolytic viruses to leverage antitumor immunity.T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.Giving oncolytic vaccinia virus more BiTE.Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery.Oncolytic Immunotherapy for Treatment of Cancer.Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses.Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy.An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites.Immune System, Friend or Foe of Oncolytic Virotherapy?Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land.Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus.Prospects for combined use of oncolytic viruses and CAR T-cells.Oncolytic Virotherapy and the Tumor Microenvironment.

P2860

Q26741020-A35FE0EC-BF1B-46CF-B6C7-39094D2154FD Q26775030-E2764D82-C065-4DB3-97AD-6B210FB8E040 Q26995905-49899A78-BCD1-40D6-90DE-DBD37272F0BD Q27002646-B027C7CD-71A5-4126-B1A9-0CFC7FABEB54 Q27025600-B2C17DC0-A450-454C-ACA7-151E057395BE Q33679505-E13FF0DB-CBF8-40EC-A2C0-09E0751FC443 Q33768177-694DA331-3481-4FCB-B929-4E4A206B0F6E Q33792344-54EA2E88-8F4B-4560-8910-F86B0A2D105C Q34205181-FEB086D6-2BDA-449E-AF63-6DD415C28B49 Q35065222-A8135400-5BCA-4DB3-A57C-8F71B6E86D1B Q35162284-A45124CF-AC48-4ED7-8D26-925F295AD395 Q36049446-C3E2B41B-3B7D-462A-829B-19FF071CFB55 Q36378248-C5E323FB-B7B2-4DF5-BB4D-6D44116F7A9F Q36520695-63C3065F-8E7E-47E8-9585-3B7497EE8669 Q36659289-063EF96A-5260-4420-9466-466E05DE9009 Q36821243-954442E3-E594-401B-BB07-B90DEA2DD0CB Q36883833-3367A3E8-D803-4E3B-8FB6-4AF1A2E104F6 Q37185612-4E71E00F-42DA-4F03-8ED8-231522233049 Q37225501-C754CB24-56BD-4092-A73C-FEBBF594E2A2 Q37707676-572E4CD3-DF61-465C-8ABD-EC35D84B6AE5 Q37982449-2936D7EB-346F-47CC-9330-54606979E9CA Q38025696-42AE7F25-DBA2-4433-A7F8-9EF07CD522A8 Q38159802-09ACD6BD-DCE1-45F0-B104-687173D8A578 Q38223419-AEF2656E-8029-41BC-AC51-B2B7185BED02 Q38225561-C7249567-5AD9-475D-9B0C-B9AC7BC26DFB Q38284345-180C79B8-4609-46DF-9452-91266813535F Q38470166-47B0F136-97B2-4919-B2AD-61283EF274CB Q38648630-ED5E488F-C90C-42B5-B2A9-E216C03F269B Q38648659-1C2B0248-C3D5-4476-9124-2CC4A40D5EB7 Q38673968-9B7195BD-29B2-4061-A28B-8E21AA844292 Q38848223-AFD227F1-E225-4970-B008-37350C20C44B Q38924539-ADA43F3D-FB63-4ABA-940F-EAD8E3CE0104 Q38924557-5CAB8001-81EE-4057-B681-FC3162DC0E2C Q38933648-AB337A62-0DAA-4428-99D0-7F6FEC628AB6 Q39355854-B3546856-9FDB-41BA-8FE8-B5F56EA8DAF1 Q39437344-727FE1E0-BD77-4A63-BEEC-68EC486F0412 Q42205615-3114EA56-49D1-4D81-B3E0-C5D8E9B7B8EA Q45325487-95384EF7-D85A-4E02-A7D9-30467A8EB985 Q47103891-685FBA7D-4445-4AC0-88E1-8CE8C2607F75 Q47560690-5BC12865-C404-4F5D-B827-9A6386C8C593

P2860

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

http://www.wikidata.org/entity/Q34757261

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

@ast

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

@en

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

@nl

type

label

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

@ast

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

@en

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

@nl

prefLabel

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

@ast

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

@en

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

@nl

P1433

Q34757261-DEDBF6C0-2566-42E4-B745-EBCE0B9D8D6F

P1476

Q34757261-08E56C83-2587-47D3-9471-46283333095E

P2093

Q34757261-19DF41EC-B8CA-4E71-857F-A859CE230FA9

Q34757261-23F90519-1324-4375-9ED6-D84226A495C6

Q34757261-73E0A4C7-D873-4E26-9086-CEB266D26D9D

Q34757261-7D1A765E-2F18-4DA7-961D-6AE1D280CF40

Q34757261-82B07D2E-1564-4986-B25B-C72954C18CEF

Q34757261-A1880E06-8ADF-4FFE-A4E4-5149E8E918B5

Q34757261-A25318F2-6C12-4C92-B083-030B1DF5B437

P2860

Q34757261-02FAC236-3833-446D-80DD-DF4D8F7897C0

Q34757261-05B88150-81A6-466A-8460-FE18CB435A41

Q34757261-0AD82501-53A0-4911-B932-14B7ED18FB8B

Q34757261-0B4AAD0E-1C4E-4C90-A222-756217542746

Q34757261-23574575-EB84-45A6-853E-CBD76F327E5D

Q34757261-23814E53-C794-4BCD-891B-C4E86CA4303D

Q34757261-3A4E07BC-41F5-46C6-A68D-804E595A59E9

Q34757261-4050653A-13F1-49E5-9501-ABAAECD8B2F4

Q34757261-40FFD4FA-6638-4AF7-9C85-25AAA3A906FA

Q34757261-4486057C-ABED-485E-B9EB-047D333B81EA

P304

Q34757261-72F877EF-111E-4329-AD7C-C5806D6CC78B

P31

Q34757261-8EF0D34F-0FC6-45FE-83B4-9F337414F866

P356

Q34757261-A28E2709-8A50-488B-876E-8EC53DA57D64

P433

Q34757261-FA0E3A64-34A7-40EA-9CF3-3808F91CD5F6

P478

Q34757261-9C3B3231-90E3-4D84-942A-6D00E7EB5D89

P50

Q34757261-E4EFC359-B50B-43B5-ADA3-847D2056826A

P577

Q34757261-F8674A27-68D2-42CF-87F5-FBA21E37A84E

P5875

Q34757261-B61D3DE7-84BA-43FE-B25A-A77C676CC788

P698

Q34757261-986EF35C-A557-4363-9D4B-75ED533726AF

P921

Q34757261-8D963841-0B9E-48F8-B255-BFFF9064D84B

P932

Q34757261-8777E39C-198F-4579-B556-2005599C355F

P356

P1433

Molecular Therapy

P1476

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer

@en

P2093

David L Bartlett

http://www.w3.org/2001/XMLSchema#string

Julie Urban

http://www.w3.org/2001/XMLSchema#string

Jun Li

http://www.w3.org/2001/XMLSchema#string

Mark O'Malley

http://www.w3.org/2001/XMLSchema#string

Pawel Kalinski

http://www.w3.org/2001/XMLSchema#string

Steve H Thorne

http://www.w3.org/2001/XMLSchema#string

Z Sheng Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Structure and Function of A41, a Vaccinia Virus Chemokine Binding Protein

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus

Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines.

Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia

Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells.

Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity

A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.

P304

650-657

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2010.312

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49785401

http://www.w3.org/2001/XMLSchema#string

P698

21266959

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

3070102

http://www.w3.org/2001/XMLSchema#string